Which has better valuation & earnings, DXCM or HAE?

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.97B 6.58 $836.30M $2.53 34.24 Haemonetics $1.35B 3.54 $97.31M $2.04 51.61

Is DXCM or HAE more profitable?

DexCom has a net margin of 20.12% compared to Haemonetics' net margin of 7.12%. DexCom's return on equity of 35.94% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Haemonetics 7.12% 27.55% 9.65%

Does the media prefer DXCM or HAE?

In the previous week, DexCom had 6 more articles in the media than Haemonetics. MarketBeat recorded 8 mentions for DexCom and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat DexCom's score of 0.82 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HQY or HAE?

HealthEquity has higher revenue and earnings than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.36B 5.36 $215.20M $2.77 31.86 Haemonetics $1.35B 3.54 $97.31M $2.04 51.61

Does the media refer more to HQY or HAE?

In the previous week, HealthEquity had 2 more articles in the media than Haemonetics. MarketBeat recorded 4 mentions for HealthEquity and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat HealthEquity's score of 0.74 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, HAE or LNTH?

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.35B 3.54 $97.31M $2.04 51.61 Lantheus $1.54B 4.22 $233.56M $4.14 24.09

Is HAE or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Haemonetics' net margin of 7.12%. Lantheus' return on equity of 28.10% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Lantheus 17.69% 28.10% 14.35%

Does the media prefer HAE or LNTH?

In the previous week, Lantheus had 11 more articles in the media than Haemonetics. MarketBeat recorded 13 mentions for Lantheus and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat Lantheus' score of 0.50 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PODD or HAE?

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $3.05B 3.09 $247.10M $5.35 25.44 Haemonetics $1.35B 3.54 $97.31M $2.04 51.61

Is PODD or HAE more profitable?

Insulet has a net margin of 12.29% compared to Haemonetics' net margin of 7.12%. Insulet's return on equity of 29.29% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to PODD or HAE?

In the previous week, Insulet had 6 more articles in the media than Haemonetics. MarketBeat recorded 8 mentions for Insulet and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat Insulet's score of 1.00 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, QTRX or HAE?

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix $138.90M 1.11 -$107.15M -$2.63 N/A Haemonetics $1.35B 3.54 $97.31M $2.04 51.61

Is QTRX or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to Quanterix's net margin of -80.25%. Haemonetics' return on equity of 27.55% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Quanterix -80.25% -26.09% -19.03% Haemonetics 7.12% 27.55% 9.65%

Does the media favor QTRX or HAE?

In the previous week, Quanterix had 2 more articles in the media than Haemonetics. MarketBeat recorded 4 mentions for Quanterix and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat Quanterix's score of 0.71 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Haemonetics (HAE) Competitors

$105.28 -0.72 (-0.68%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$105.39 +0.11 (+0.10%)

As of 09/25/2026 07:30 PM Eastern

Compare

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you buy Haemonetics stock or one of its competitors? Haemonetics's main competitors and comparable companies include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Haemonetics compare to DexCom?

DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.97B	6.58	$836.30M	$2.53	34.24
Haemonetics	$1.35B	3.54	$97.31M	$2.04	51.61

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DexCom presently has a consensus price target of $89.08, suggesting a potential upside of 2.84%. Haemonetics has a consensus price target of $99.78, suggesting a potential downside of 5.23%. Given DexCom's stronger consensus rating and higher possible upside, equities analysts clearly believe DexCom is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.92
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

DexCom has a net margin of 20.12% compared to Haemonetics' net margin of 7.12%. DexCom's return on equity of 35.94% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Haemonetics	7.12%	27.55%	9.65%

In the previous week, DexCom had 6 more articles in the media than Haemonetics. MarketBeat recorded 8 mentions for DexCom and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat DexCom's score of 0.82 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

DexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

HealthEquity presently has a consensus price target of $112.20, suggesting a potential upside of 27.14%. Haemonetics has a consensus price target of $99.78, suggesting a potential downside of 5.23%. Given HealthEquity's stronger consensus rating and higher possible upside, research analysts plainly believe HealthEquity is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

HealthEquity has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

HealthEquity has higher revenue and earnings than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.36B	5.36	$215.20M	$2.77	31.86
Haemonetics	$1.35B	3.54	$97.31M	$2.04	51.61

HealthEquity has a net margin of 17.36% compared to Haemonetics' net margin of 7.12%. Haemonetics' return on equity of 27.55% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.36%	15.33%	9.51%
Haemonetics	7.12%	27.55%	9.65%

In the previous week, HealthEquity had 2 more articles in the media than Haemonetics. MarketBeat recorded 4 mentions for HealthEquity and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat HealthEquity's score of 0.74 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.6% of HealthEquity shares are held by company insiders. Comparatively, 2.1% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

HealthEquity beats Haemonetics on 9 of the 16 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Haemonetics (NYSE:HAE) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Haemonetics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 11 more articles in the media than Haemonetics. MarketBeat recorded 13 mentions for Lantheus and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat Lantheus' score of 0.50 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.35B	3.54	$97.31M	$2.04	51.61
Lantheus	$1.54B	4.22	$233.56M	$4.14	24.09

Lantheus has a net margin of 17.69% compared to Haemonetics' net margin of 7.12%. Lantheus' return on equity of 28.10% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Lantheus	17.69%	28.10%	14.35%

Haemonetics currently has a consensus target price of $99.78, suggesting a potential downside of 5.23%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 8.39%. Given Lantheus' higher possible upside, analysts clearly believe Lantheus is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lantheus beats Haemonetics on 9 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Insulet (NASDAQ:PODD) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

In the previous week, Insulet had 6 more articles in the media than Haemonetics. MarketBeat recorded 8 mentions for Insulet and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat Insulet's score of 1.00 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$3.05B	3.09	$247.10M	$5.35	25.44
Haemonetics	$1.35B	3.54	$97.31M	$2.04	51.61

99.7% of Haemonetics shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Insulet currently has a consensus target price of $195.40, indicating a potential upside of 43.54%. Haemonetics has a consensus target price of $99.78, indicating a potential downside of 5.23%. Given Insulet's higher probable upside, equities analysts clearly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Insulet has a net margin of 12.29% compared to Haemonetics' net margin of 7.12%. Insulet's return on equity of 29.29% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
Haemonetics	7.12%	27.55%	9.65%

Summary

Insulet beats Haemonetics on 10 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

In the previous week, Quanterix had 2 more articles in the media than Haemonetics. MarketBeat recorded 4 mentions for Quanterix and 2 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.22 beat Quanterix's score of 0.71 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.11	-$107.15M	-$2.63	N/A
Haemonetics	$1.35B	3.54	$97.31M	$2.04	51.61

Quanterix has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Haemonetics has a net margin of 7.12% compared to Quanterix's net margin of -80.25%. Haemonetics' return on equity of 27.55% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Haemonetics	7.12%	27.55%	9.65%

Quanterix presently has a consensus price target of $3.00, indicating a potential downside of 8.26%. Haemonetics has a consensus price target of $99.78, indicating a potential downside of 5.23%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Haemonetics beats Quanterix on 15 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.79B	$5.56B	$7.33B	$22.98B
Dividend Yield	N/A	1.79%	2.52%	3.69%
P/E Ratio	51.61	25.31	275.82	28.00
Price / Sales	3.54	90.51	649.60	83.10
Price / Cash	13.89	32.91	79.52	41.27
Price / Book	6.14	5.77	10.44	4.66
Net Income	$97.31M	$151.55M	$3.51B	$1.07B
7 Day Performance	-2.93%	-0.97%	-1.31%	-1.12%
1 Month Performance	0.23%	-4.40%	-4.61%	-5.10%
1 Year Performance	118.45%	7.68%	15.01%	7.73%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	1.8126 of 5 stars	$105.28 -0.7%	$99.78 -5.2%	+118.4%	$4.79B	$1.35B	51.61	3,009
DXCM DexCom	3.3593 of 5 stars	$89.17 -0.2%	$89.08 -0.1%	+29.1%	$33.72B	$4.66B	35.25	11,000
HQY HealthEquity	4.324 of 5 stars	$94.52 -0.7%	$112.20 +18.7%	-8.6%	$7.87B	$1.31B	34.12	2,814
LNTH Lantheus	3.2814 of 5 stars	$100.28 -0.3%	$108.11 +7.8%	+97.1%	$6.56B	$1.54B	24.22	1,193	News Coverage Analyst Upgrade
PODD Insulet	4.0885 of 5 stars	$140.53 0.0%	$195.40 +39.0%	-57.2%	$9.75B	$2.71B	26.27	5,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Which has better valuation & earnings, DXCM or HAE?

Do institutionals & insiders hold more shares of DXCM or HAE?

Do analysts recommend DXCM or HAE?

Is DXCM or HAE more profitable?

Does the media prefer DXCM or HAE?

Which has more volatility & risk, DXCM or HAE?

Summary

How does Haemonetics compare to HealthEquity?

Do analysts rate HQY or HAE?

Which has more volatility and risk, HQY or HAE?

Which has higher valuation and earnings, HQY or HAE?

Is HQY or HAE more profitable?

Does the media refer more to HQY or HAE?

Do institutionals & insiders have more ownership in HQY or HAE?

Summary

How does Haemonetics compare to Lantheus?

Which has more volatility & risk, HAE or LNTH?

Does the media prefer HAE or LNTH?

Which has preferable earnings and valuation, HAE or LNTH?

Is HAE or LNTH more profitable?

Do analysts recommend HAE or LNTH?

Do institutionals & insiders have more ownership in HAE or LNTH?

Summary

How does Haemonetics compare to Insulet?

Does the media refer more to PODD or HAE?

Which has more risk & volatility, PODD or HAE?

Which has better earnings & valuation, PODD or HAE?

Do institutionals & insiders have more ownership in PODD or HAE?

Do analysts rate PODD or HAE?

Is PODD or HAE more profitable?

Summary

How does Haemonetics compare to Quanterix?

Does the media favor QTRX or HAE?

Do insiders & institutionals believe in QTRX or HAE?

Which has stronger earnings and valuation, QTRX or HAE?

Which has more volatility and risk, QTRX or HAE?

Is QTRX or HAE more profitable?

Do analysts recommend QTRX or HAE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools